|
Health Condition(s) or Problem
|
Dyspnea; Lung Cancer; Metastatic Cancer
|
|
Lay Summary
|
RATIONALE: Gathering information about experiences of episodic breathlessness in patients
with advanced disease may help doctors learn more about the disease.
PURPOSE: This clinical trial is studying experiences of episodic breathlessness in patients
with lung cancer or other advanced disease.
(from ClinicalTrials.gov)
|
|
Who can enter the trial
|
DISEASE CHARACTERISTICS:
- Diagnosis of advanced disease as defined by the following criteria:
- Lung cancer
- Primary lung cancer at all stages (small cell lung cancer [SCLC] and
non-small cell lung cancer [NSCLC])
- Cancer at any site with secondary tumor of the lung (lung metastasis)
- Chronic obstructive pulmonary disease (COPD)
- Stage III or IV of the Global Initiative for Obstructive Lung Disease
(GOLD) classification, which includes the airflow limitation measured by
spirometry FEV1 < 50%, FEV1/FVC < 0.7, and symptoms such as more severe
breathlessness, reduced exercise capacity, and repeated exacerbations
- Chronic heart failure (CHF)
- NYHA class II-IV heart disease, which includes symptoms such as dyspnea or
palpitation and an increasing limitation of exercise capacity or discomfort
at rest
- Motor neuron disease (MND)
- All patients suffering from breathlessness
- Suffering from episodic breathlessness as defined above at any level of severity
PATIENT CHARACTERISTICS:
- Able to give informed consent
- Able to be interviewed
- No cognitive impairment (clinically judged by the principal investigator)
- No limited comprehension of the English language
PRIOR CONCURRENT THERAPY:
- Concurrent disease-oriented therapies (e.g., chemotherapy, radiotherapy, or surgery)
allowed
|
|
Who cannot enter the trial
|
DISEASE CHARACTERISTICS:
- Diagnosis of advanced disease as defined by the following criteria:
- Lung cancer
- Primary lung cancer at all stages (small cell lung cancer [SCLC] and
non-small cell lung cancer [NSCLC])
- Cancer at any site with secondary tumor of the lung (lung metastasis)
- Chronic obstructive pulmonary disease (COPD)
- Stage III or IV of the Global Initiative for Obstructive Lung Disease
(GOLD) classification, which includes the airflow limitation measured by
spirometry FEV1 < 50%, FEV1/FVC < 0.7, and symptoms such as more severe
breathlessness, reduced exercise capacity, and repeated exacerbations
- Chronic heart failure (CHF)
- NYHA class II-IV heart disease, which includes symptoms such as dyspnea or
palpitation and an increasing limitation of exercise capacity or discomfort
at rest
- Motor neuron disease (MND)
- All patients suffering from breathlessness
- Suffering from episodic breathlessness as defined above at any level of severity
PATIENT CHARACTERISTICS:
- Able to give informed consent
- Able to be interviewed
- No cognitive impairment (clinically judged by the principal investigator)
- No limited comprehension of the English language
PRIOR CONCURRENT THERAPY:
- Concurrent disease-oriented therapies (e.g., chemotherapy, radiotherapy, or surgery)
allowed
|
|
What will happen
|
Other; medical chart review; Other; study of socioeconomic and demographic variables; Other; survey administration; Procedure; quality-of-life assessment
|
|
Primary aim
|
Experiences of episodic breathlessness; Impact of episodic breathlessness on daily living; Individual coping strategies to reduce burden of episodic breathlessness
|
|
Secondary Aim
|
Sorry, not currently available
|
|
Participant Information Sheet
|
Sorry, not currently available
|
|
Website
|
http://cancer.gov/clinicaltrials/UKM-KCH-EB-V4
|
|
Recruitment Status
|
Recruiting
|
|
Nation
|
England
|
|
Location
|
London
|